IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by First American Trust FSB

First American Trust FSB lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,846 shares of the medical research company’s stock after selling 726 shares during the period. First American Trust FSB’s holdings in IQVIA were worth $6,455,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the 4th quarter worth about $33,000. Avior Wealth Management LLC grew its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth $44,000. Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV opened at $186.35 on Tuesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $254.54. The business’s fifty day moving average price is $194.58 and its 200 day moving average price is $207.73. The stock has a market capitalization of $32.86 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent research reports. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.